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Candida blankii: an emergent opportunistic
yeast with reduced susceptibility to
antifungals
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Gilda M. B. Del Negro1, Viviane F. Gimenes2, Rafaella C. Grenfell 5, Adriana L. Motta1, Flávia Rossi1 and Gil Benard2
In 1968, Buckley and van Uden described the non-
fermenting yeast Candida blankii (C. blankii) found in
the organs of a mink1. Until recently, this microorgan-
ism had only been the subject of biotechnological
research2,3. However, in 2015, Zaragoza et al. reported a
14-year-old male patient with cystic fibrosis (CF), who
had pulmonary exacerbations with repeated isolation of
C. blankii from respiratory samples4. This finding raised
the hypothesis that this yeast could be a relevant
pathogen for CF patients4.This paper corroborates this
initial observation by describing a bloodstream infection
by C. blankii in a CF patient who underwent lung
transplantation.
A 16-year-old female with CF was referred to our lung
transplant center in March 2016. Her recent medical
history was notable for severe pulmonary exacerbations,
which required prolonged hospitalization and mechanical
ventilation. Her most recent preadmission sputum cul-
tures collected by the referring hospital showed positive
for Staphylococcus aureus, Pseudomonas aeruginosa,
Burkholderia cepacia, Aspergillus sp., including positive
samples for Candida sp. (negative germ tube, isolates
not available) collected after itraconazole therapy
(200 mg/day) used to treat the pulmonary exacerbations.
In June 2016, she underwent bilateral lung transplantation
at the Hospital das Clínicas, University of São Paulo,
Brazil, under antimicrobial prophylaxis consisting of
teicoplanin, meropenem, cotrimoxazole and liposomal
amphotericin B (L-AMB, 200 mg/day). However, during
the infusion of L-AMB, the patient presented hypoten-
sion, leading to the discontinuation of the antifungal
treatment. On the first postoperative day (POD), the
patient developed sepsis, and so blood cultures were
collected (Bactec aerobic and anaerobic/Plus, BD).
Peripheral and central venous catheter blood cultures
became positive for yeasts after 41 (anaerobic bottle) and
72 (aerobic bottles) hours of incubation, respectively. On
the third POD, due to the provisional report of yeasts on
blood cultures, micafungin (100 mg/day) was prescribed.
Blood cultures collected 72 h after the introduction of
micafungin became negative; transthoracic echocardio-
graphy and fundoscopic eye exam did not show any sig-
nificant results. The yeast isolate showing pale pink
colonies on chromogenic medium (BBL CHROMagar,
BD, Sparks, USA) were not identified by MALDI-TOF
mass spectrometry (Vitek MS™, IVD library, bioMérieux,
Marcy-L´Etoile, France). Because clinical improvement
was observed, micafungin was maintained for 14 days.
The patient was discharged on the 39th POD.
The clinical isolate (HCFMUSP01) was later identified
as C. blankii after sequence analysis of the internal tran-
scribed spacer 1 (ITS1, GenBank accession no.
MF573785) and D1D2 region from the 26S subunit
(D1D2, GenBank accession no. MF940140) of the
rRNA5,6. Since little is known about this microorganism
as an opportunistic pathogen, we further characterized
this species in terms of genetic and proteomic diversity,
antifungal susceptibility, biofilm production, and in vivo
virulence by analyzing the clinical isolate and the strains
(IIC1M.1, BX90C, BX81A) from the yeast collection at the
Federal University of Minas Gerais, Brazil.
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The organisms had identical D1D2 rRNA sequences, but
the clinical isolate showed a different ITS allele (single
nucleotide deletion) when compared to the other strains
(Table 1 and supplementary Table S1). Proteomic analysis
by MALDI-TOF mass spectrometry (MS), this time using
both Bruker’s (Microflex™, Bruker Daltonics, Bremen,
Germany) and bioMérieux instruments (Vitek MS™, bio-
Mérieux, Marcy L’Etoile, France), revealed distinct spectral
profiles between clinical and environmental organisms
(Supplementary Figure S1). As an observation, the Bruker’s
IVD and RUO libraries lacked this species and were unable
to identify the organisms, whilst the Vitek MS™ RUO
library correctly identified all of them (Table 1).
Antifungal susceptibility testing was carried out using
the EUCAST reference broth microdilution method7. All
organisms showed high minimal inhibitory concentra-
tions (MICs) of fluconazole (Sigma-Aldrich, St. Louis,
MO, USA) (16 mg/L) and voriconazole (Sigma-Aldrich)
(0.5 mg/L), whereas amphotericin B (Sigma) exhibited
potent activity (0.25–0.5 mg/L). Both anidulafungin (Pfi-
zer, Groton, CT, USA) and micafungin (Astellas Pharma
US, Northbrook, IL, USA) showed limited activity against
C. blankii organisms, with MICs raging from 0.25–1mg/L
and 0.25–0.5 mg/L, respectively (Table 1).
Biofilm formation and metabolic activity were measured
by using crystal violet staining8 and XTT reduction assay9,
respectively. Based on previously reported cutoff values10,
all organisms were classified as low biofilm producers,
showing low metabolic activity (Supplementary Figure S2).
Killing assays in Galleria mellonella model were per-
formed to compare the pathogenicity of C. blankii organ-
isms with Candida albicans (strain SC5314)11. Sixteen G.
mellonella larvae (LFDP/ICB/USP) were used for each test
group. Larvae were inoculated (1× 105 and 1× 106 cells/
larva) and incubated at 37 °C. Pathogenicity was assessed,
monitoring the percent survival over 7 days and plotted
using Kaplan–Meier and the Log-rank test (GraphPadPrism
4, GraphPad Software, Inc., La Jolla, USA). The C. blankii
organisms HCFMUSP01 and IIC1M.1 were significantly
less virulent than the C. albicans strain (P< 0.0001) in the
G. mellonella model (Supplementary Figure S3). However,
the strains BX 90C and BX 81A showed similar patho-
genicity when compared to C. albicans (P= 0.13). More-
over, G. mellonella killing by different C. blankii organisms
were accentuated when larvae were inoculated with 1× 106
organisms (Supplementary Figure S3).
Evidence is provided here that C. blankii is an opportunist
pathogen for lung transplant and/or CF patients. Clinical
laboratories from referral centers of CF and lung transplant
should be aware of this Candida species, and the fact that
not all MALDI-TOF MS libraries are able to identify it.
Based on our case report and the in vitro data presented
here, we suggest that CVC was not the primary source of
the infection and that the patient’s respiratory tract wasTa
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heavily colonized by C. blankii (assuming that the Candida
sp. from the referring hospital was C. blankii and based on
G. mellonella killing assays). This probably led the patient to
develop fungemia due to the lack of antifungal prophylaxis.
Further studies of different strains are warranted to increase
knowledge of genetic diversity and antifungal susceptibility
profile of C. blankii organisms. However, while more micro-
biological data are pending, it is prudent to avoid azoles for the
treatment or prophylaxis of C. blankii infections. Like Can-
dida parapsilosis, despite the reduced antifungal action of
echinocandins against C. blankii, successful treatment may be
achieved with these compounds, as illustrated in this report.
However, amphotericin B showed strong in vitro activity
against C. blankii, and its formulations should be the first line
therapy for deep-seated infections by this emergent species
while antifungal susceptibility testing is ongoing.
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